US biotech OPKO Health has said it will continue with clinical development of its long-acting human growth hormone product (hGH-CTP), even though it has failed in a late stage trial in adul
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
